Effect of Epoetin Alfa and Sodium Valproate in Patients with Myelodysplastic Syndrome
Novelty in Biomedicine,
Vol. 8 No. 4 (2020),
29 November 2020
,
Page 151-155
https://doi.org/10.22037/nbm.v1i1.27537
Abstract
Background: Myelodysplastic syndrome (MDS) is an important precancerous disease leading to blood malignancies. Prompt diagnosis and treatment would result in better outcome in patients. Purpose of the study was to determine the effect of Epoetin Alfa and Sodium Valproate in patients with MDS.Materials and Methods: In this interventional quasi-experimental study, 50 consecutive patients with MDS from Taleghani Hospital (Tehran, Iran) in 2016-2017 were enrolled. They underwent treatment for eight months with 10000 units per month from Epoetin Alfa plus 200 mg TDS from Sodium Valproate. The hematological response was determined according to the hemoglobin, platelet, and neutrophil.
Results: Hematological response was present in 68%. The packed cell treatment were decreased significantly (P=0.040) and 56% of patients had no receipt of packed cells after treatment.
Conclusion: It is concluded that Epoetin Alfa plus Sodium Valproate was effective in treatment of patients with Myelodysplastic syndrome and use of this combination therapy is recommended.
- Epoetin Alfa, Sodium Valproate, Myelodysplastic Syndrome
How to Cite
References
References
Faderl S. Kantarjian H. Myelodysplastic Syndromes. In: DeVita V, Lawrence T, Rosenberg S. Cancer Principles and Practice of Oncology. 9th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2011. p. 1988-96.
Silverman L. The Myelodysplastic Syndrome. In: Hong WK, Blast RC, Hait WN. Cancer Medicine. 8th edition. Shelton, CT: People's Medical Publishing House-USA; 2010. p. 1544-58.
Foran JM, Sekeres MA. Myelodysplastic Syndromes. In: Aberloff M, Armitage J, Niederhuber J, Kastan M, McKenna W. Abeloff's Clinical Oncology. 4th edition. Churchill Livingstone Elsevier; Philadelphia, PA: 2008. p. 2235-9.
Davidoff AJ, Weiss SR, Baer MR, Ke X, Hendrick F, Zeidan A, et al. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leuk Res. 2013; 37:675-80.
Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Nat Cancer Inst. 2008;100:1542-51.
Greenberg PL, Sun Z, Miller KB, Bennett JM, Tallman MS, Dewald G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009;114:2393-400.
Steensma DP. Hematopoietic growth factors in myelodysplastic syndromes. Semin Oncol. 2011;38:635-47.
Musto P, Falcone A, Sanpaolo G, Bodenizza C, La Sala A, Perla G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol. 2003;122:269-71.
Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111:574-82.
Hoefsloot LH, van Amelsvoort MP, Broeders LC, van der Plas C, van Lom K, Hoogerbrugge H, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood. 1997;89:1690-700.
Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood. 2004;104(5):1266-9.
Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, et al. Results of Phase II Randomized Study of Low-Dose Decitabine with or without Valproic Acid in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Cancer. 2015;121(4):556-61.
Duong VH, Baer MR, Hendrick F, Weiss SR, Sato M, Zeidan AM, et al. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response. Leuk Res. 2015;39(6):586-91.
Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol. 2000;22:62-5.
Gesundheit B, Kirby M, Lau W, Koren G, Abdelhaleem M. Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment. J Pediatr Hematol Oncol. 2002;24(7):589-90.
Kuendgen A, Knipp S, Fox F, Strupp C, Hildebrandt B, Steidl C, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84:61-6.
Kuendgen A, Bug G, Ottmann OG, Haase D, Schanz J, Hildebrandt B, et al. Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid. Clin Epigenetics. 2011;2(2):389-99.
Hellström-Lindberg E, van de Loosdrecht A. Erythropoiesis stimulating agents and other growth factors in low-risk MDS. Best Pract Res Clin Haematol. 2013;26(4):401-10.
Toma A, Kosmider O, Chevret S, Delaunay J, Stamatoullas A, Rose C, et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia. 2016;30(4):897-905.
Park S, Greenberg P, Yucel A, Farmer C, O'Neill F, De Oliveira Brandao C, et al. Clinical effectiveness and safety of erythropoietin-stimulating agents for the treatment of low- and intermediate-1-risk myelodysplastic syndrome: a systematic literature review. Br J Haematol. 2019184(2):134-60.
Park S, Hamel JF, Toma A, Kelaidi C, Thépot S, Campelo MD, et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. J Clin Oncol. 2017; 35(14):1591-7.
Ornstein MC, Mukherjee S, Sekeres MA. More is better: combination therapies for myelodysplastic syndromes. Best Pract Res Clin Haematol. 2015;28(1):22-31.
Poloni A, Costantini B, Mariani M, Leoni P. Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature. Leuk Res Rep. 2013; 2(2):44-6.
Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: A phase II trial in 281 patients. Br J Haematol.. 2002;118:174–8.
- Abstract Viewed: 207 times
- PDF Downloaded: 119 times